The offering is highly dilutive—over 12 million new shares issued at $142 represents ~8.5% dilution assuming ~143 million prior shares outstanding. While the cash strengthens the balance sheet for late-stage trials, the scale of dilution outweighs benefits in the near term. Traders should monitor short-term price pressure and assess whether future R&D milestones can offset sentiment around dilution.
Price Chart
Executive Summary
Revolution Medicines raised approximately $2.225 billion through a concurrent public offering of common stock and convertible notes, with net proceeds of $2.137 billion. The capital raise includes 12.15 million shares at $142 per share and $500 million in 0.50% convertible senior notes due 2033, marking a significant dilutive financing event. The funds will support R&D and commercialization efforts for its RAS-addicted cancer therapies.
Key Financial Metrics
Key Facts
- Closed concurrent public offerings: 12,147,887 shares of common stock at $142/share and $500 million in 0.50% convertible senior notes due 2033
- Gross proceeds: $2.225 billion; net proceeds: $2.137 billion after underwriting discounts and expenses
- Convertible notes have a 0.50% coupon, mature May 1, 2033, and initial conversion price of $198.80 per share (40% premium to stock offering price)
- Proceeds to be used for R&D, potential commercialization, G&A, and capital expenditures
- J.P. Morgan, TD Cowen, and Guggenheim Securities acted as book-running managers
Financial Impact
Approximately $2.137 billion in net proceeds, but with substantial near-term dilution from equity issuance and potential future dilution from convertible notes
Risk Factors
- Significant shareholder dilution from equity issuance
- Future equity conversion risk from notes if stock price rises, increasing potential share count by ~2.5 million at initial conversion rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276479 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.64 (+5.47%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.64 (+5.47%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.64 (+0.87%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.64 (+0.87%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.64 (−4.08%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.64 (−4.08%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.64 (−2.24%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.64 (+9.19%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.64 (+10.20%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.64 (+24.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access